EcoDrugPlus

Phosphodiesterase 7a

Ensembl ID : ENSSAUG00010025870
Gene Symbol: PDE7A
3 Cross references
227 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSSAUG00010015069
Gene Symbol: PDE7B
3 Cross references
189 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSSAUG00010022783
Gene Symbol: PDE9A
1 Cross references
185 Possible Orthologues:

Phosphoinositide 3-Kinase Regulatory Subunit 5-Like

Ensembl ID : ENSSAUG00010002823
Gene Symbol: LOC115576345
2 Cross references
185 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSSAUG00010007407
Gene Symbol: PIK3R3
3 Cross references
206 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSSAUG00010012678
Gene Symbol: PIK3R3
3 Cross references
171 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSSAUG00010010217
Gene Symbol: PIK3R5
3 Cross references
200 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 1 (Alpha)

Ensembl ID : ENSSAUG00010016157
Gene Symbol: PIK3R1
1 Cross references
202 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 1 (Alpha)

Ensembl ID : ENSSAUG00010005793
Gene Symbol: PIK3R1
1 Cross references
53 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSSAUG00010011236
Gene Symbol: PLA2G7
3 Cross references
203 Possible Orthologues:

Phospholipase A2-Like

Ensembl ID : ENSSAUG00010003563
Gene Symbol: LOC115575937
3 Cross references
232 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase

Ensembl ID : ENSSAUG00010020550
Gene Symbol: GART
1 Cross references
246 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).